ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO539

PTH, FGF23, and Effects of Intensive Blood Pressure Lowering in SPRINT Participants with CKD

Session Information

Category: Hypertension

  • 1104 Hypertension: Clinical and Translational - Salt and Hypertension


  • Ginsberg, Charles, UCSD, San Diego, California, United States
  • Craven, Timothy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
  • Chonchol, Michel, University of Anschutz Medical Center, Aurora, Colorado, United States
  • Cheung, Alfred K., University of Utah, Salt Lake City, Utah, United States
  • Sarnak, Mark J., Tufts Medical Center, Boston, Massachusetts, United States
  • Killeen, Anthony Alexander, University of Minnesota, Minneapolis, Minnesota, United States
  • Raphael, Kalani L., VA Salt Lake City Health Care System, Salt Lake City, Utah, United States
  • Bhatt, Udayan Y., The Ohio State University, Dublin, Ohio, United States
  • Chen, Jing, Tulane School of Medicine, New Orleans, Louisiana, United States
  • Chertow, Glenn Matthew, Stanford University School of Medicine, Palo Alto, California, United States
  • Freedman, Barry I., Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
  • Oparil, Suzanne, University of Alabama at Birmingham , Birmingham, Alabama, United States
  • Wall, Barry M., VA Medical Center, Memphis, Tennessee, United States
  • Wright, Clinton B., NINDS, Rockville, Maryland, United States
  • Shlipak, Michael, San Francisco VA Medical Center, San Francisco, California, United States
  • Ix, Joachim H., UCSD, San Diego, California, United States

Serum FGF23 and PTH levels are elevated in CKD patients, and are associated with CVD events. Prior work has demonstrated that the association with CVD events may be modified by tubular resistance to FGF-23, thereby giving insight into kidney tubule function above and beyond eGFR. We hypothesized that the therapeutic benefits of intensive blood pressure (BP) control may also be modified by tubular resistance to PTH and FGF-23.


Among 2486 SPRINT participants with baseline eGFR < 60 ml/min/1.73m2, we measured intact FGF23 and intact PTH. We evaluated whether the effect of randomization to intensive vs. standard BP arms on CVD, HF events, and all-cause mortality was modified by serum PTH or FGF-23 levels.


Mean age was 73 yrs, 60% were female, mean eGFR was 46±9 ml/min/1.73m2. Median [IQR] iFGF23 was 66 [52, 88] pg/ml, and median iPTH was 48 [35, 67] pg/ml. PTH modified the effect of intensive BP lowering for CVD events (pint=0.01) and HF (pint=0.003). In stratified analyses, intensive BP lowering was associated with lower risk of CVD (HR 0.68, 95% CI 0.45-1.00) and HF (HR 0.41, 95% CI 0.20-0.85) among participants with PTH <48 pg/ml; but not those with PTH >48 pg/ml. FGF23 did not modify the association of intensive BP control with any of the 3 outcomes.


Lower serum PTH levels may identify a subset of CKD patients who receive the greatest benefit from intense BP lowering. Further work is necessary to elucidate if tubular resistance to PTH is the mechanism responsible for these findings.

Effect of Randomization to Intensive Blood Pressure Lowering for CVD and HF Events, Stratified by PTH Above vs. Below the Median
 Standard Arm
# Event / # At Risk
HR* (95% CI)
Intensive Arm
# Event / # At Risk
HR* (95% CI)
CVD Events  
≤ Median
1.00 (Reference)
0.67 (0.45, 1.00)
> Median
1.00 (Reference)
1.02 (0.72, 1.42)
Heart Failure Events  
≤ Median
1.00 (Reference)
0.41 (0.20, 0.85)
> Median
1.00 (Reference)
0.93 (0.55, 1.58)

Models adjusted for age, gender, race, randomized treatment arm, eGFR-Cr-Cys, urine ACR, prevalent CVD, prevalent HF, SBP, # anti-hypertensive meds at baseline, smoking, BMI, Total chol., HDL chol.


  • NIDDK Support